Valuation of Warrants and Stock Appreciation Rights under Ind AS 102 — Option Pricing, Vesting Conditions, and Financial Reporting

Warrants and Stock Appreciation Rights occupy a distinct analytical space within equity-based compensation that is often conflated with standard ESOP valuation — and the conflation is costly. While the broad framework of Ind AS 102 (Share-Based Payments) applies to both, the specific valuation inputs, the treatment of vesting conditions, the accounting recognition pattern, and the financial statement impact differ in ways that matter significantly for companies reporting under Ind AS and for the registered valuers and auditors who must support that reporting.

A warrant, in the Indian corporate context, is a right granted by a company to a holder — typically an investor, a lender, or a strategic partner — to subscribe to equity shares at a predetermined price within a specified period. Unlike an ESOP, which is granted to employees and carries employment-based vesting conditions, a warrant is typically a standalone financial instrument whose fair value at the grant date drives accounting recognition. Under Ind AS 102, equity-settled share-based payments to non-employees must be measured at the fair value of the goods or services received, unless that fair value cannot be reliably estimated, in which case the fair value of the equity instrument granted is used as the reference. For investor warrants issued as part of a structured financing — common in Mumbai’s private credit and mezzanine financing market — the warrant is a component of a compound instrument, and its fair value at issuance must be bifurcated from the host debt instrument under Ind AS 32.

Option Pricing Models for Warrants and SARs — Black-Scholes, Binomial, and When to Use Each

The fair value of a warrant is determined using an option pricing model. The Black-Scholes model is the simplest and most widely applied, but it is appropriate only for European-style warrants — those exercisable only at expiry — with non-market vesting conditions and no path-dependency. For warrants with American-style exercise rights (exercisable at any time before expiry), or warrants with complex exercise triggers linked to performance milestones or financing events, a binomial lattice model or Monte Carlo simulation is more appropriate. The binomial model builds a price tree that models the underlying equity value at each time step, allowing early exercise to be captured at each node by comparing the immediate exercise value against the continuation value. The Monte Carlo simulation is used when the exercise condition is path-dependent — for example, when exercise is permitted only if the company achieves a revenue threshold or receives a specified external valuation in a subsequent funding round.

The key inputs to warrant valuation require particular care in the Indian private company context. The underlying equity value per share — which serves as the equivalent of the stock price in listed company option pricing — must be independently assessed by a registered valuer, since there is no market price. The expected volatility — which captures the range of outcomes for the underlying equity value — cannot be observed directly for unlisted companies, and must be estimated from a peer group of comparable listed companies, with careful consideration of the private company’s liquidity discount, capital structure differences, and stage of development. Using listed company volatility directly without adjustment for private company characteristics is one of the most common methodological errors in Indian warrant valuation, and it is one that sophisticated auditors at Big 4 firms will challenge during the Ind AS 102 review.

Stock Appreciation Rights are cash-settled share-based payments — the holder receives the appreciation in the company’s share value above the strike price in cash, rather than in shares. Under Ind AS 102, cash-settled SBPs are remeasured at fair value at each reporting date until the liability is settled, with changes in fair value recognised in profit or loss. This means that unlike equity-settled instruments — where the fair value is locked at grant date and the subsequent change in value does not affect reported profit — cash-settled SARs create mark-to-market P&L volatility that flows through every set of financial statements until the SAR is exercised or lapses. For Mumbai-based companies that have granted SARs to senior management as a performance retention tool — increasingly common in financial services, real estate, and infrastructure businesses — the accounting volatility generated by SAR remeasurement can be material, and its direction depends on how the underlying equity value moves. When equity value rises, SAR liability increases and a charge flows through P&L. When equity value falls, the reversal releases income. The registered valuer’s periodic equity valuation report is therefore a direct driver of reported profit or loss in every period — a responsibility that underscores why the analytical rigour of the equity valuation must match the financial reporting stakes involved.

For non-market performance conditions — vesting tied to revenue targets, EBITDA thresholds, or headcount milestones — the Ind AS 102 accounting requires that the grant-date fair value be estimated assuming the performance condition will be met, and then the number of instruments expected to vest is adjusted at each reporting date based on the latest estimate of whether the condition will be satisfied. Market conditions — vesting tied to the company’s share price or total shareholder return — must be incorporated directly into the option pricing model at grant date using Monte Carlo simulation, and subsequent changes in the probability of achieving the market condition do not affect the cumulative expense recognised. This distinction between market and non-market conditions is one of the most technically nuanced aspects of Ind AS 102, and correctly distinguishing between the two determines whether the valuation is a one-time grant-date exercise or an ongoing probability-weighted assessment at each reporting date.

The treatment of market conditions in equity-settled share-based payments under Ind AS 102 is one of the more technically precise distinctions in the standard, with direct implications for how the valuation is performed and how the accounting expense is recognised. A market condition is a vesting condition that is linked to the market price of the company’s equity — for example, a condition that options vest only if the company’s share price exceeds a specified level, or if total shareholder return exceeds a benchmark index over the vesting period. Non-market conditions include time-based vesting, revenue targets, headcount milestones, and other performance metrics that do not directly reference the equity market price.

Under Ind AS 102, market conditions must be incorporated directly into the fair value of the option at the grant date, using a model that captures the probability of the market condition being achieved — typically a Monte Carlo simulation or a binomial model with a performance barrier. The accounting consequence is that the grant-date fair value, incorporating the probability of meeting the market condition, is recognised as an expense over the vesting period regardless of whether the market condition is ultimately met. If the share price fails to achieve the target and the options lapse, no expense reversal is permitted — the cost has been recognised, and the economic reality that the employee did not receive the benefit is not reflected in the income statement. This asymmetric treatment surprises many compensation committees and CFOs who expect that lapsed options result in expense reversal.

For unlisted companies where market conditions are less common but where conditions tied to external investment events — such as options that vest upon an IPO or a qualifying investment at a minimum valuation — are becoming more prevalent, the option pricing challenge is particularly complex. A vesting condition tied to an IPO at a valuation above Rs 500 crore is simultaneously a market condition (it references equity valuation) and an event condition (it depends on the occurrence of a specific transaction). Modelling the probability and timing of such conditions requires assumptions about the company’s equity growth trajectory, the probability of IPO under different business scenarios, and the expected timeline to the event — all of which carry substantial uncertainty for early-stage companies. The Black-Scholes model cannot accommodate path-dependent conditions of this type; the Monte Carlo simulation framework, which models thousands of equity value trajectories under different assumptions, is the appropriate tool.

Our valuation team at Harshul Mangal & Associates provides grant-date equity valuations and option pricing for Ind AS 102 compliance — including warrant fair values, SAR liability remeasurement, and ESOP scheme design support — backed by our IBBI Registered Valuer credential (Reg. No. IBBI/RV/16/2025/16044) and experience with listed and pre-IPO company equity structures.

For further reading on the regulatory framework governing this area, refer to the ICAI guidance on Ind AS 102 — Share-Based Payment, which provides the primary regulatory foundation for the analysis discussed here.

Our Valuation for Regulatory Purposes covers the full range of assignments described in this post. If you need professional valuation assistance, we would be pleased to assist. You can reach out to us here or write to harshulmangal.ca@gmail.com.

Warrant Repricing, Modification Accounting and Board Considerations

The repricing of warrants — reducing the exercise price to reflect changed market conditions or to retain employee retention effectiveness — is among the most common ESOP-related modifications encountered in practice, and Ind AS 102’s treatment of warrant repricing is both specific and consequential. When a company reduces the exercise price of an outstanding warrant, the incremental fair value — the difference between the fair value of the modified warrant and the fair value of the original warrant at the modification date — must be recognised as an additional compensation expense over the remaining vesting period. The incremental fair value is non-reversible even if the employee subsequently leaves before vesting or if the warrant ultimately expires out of the money. Companies that have informally adjusted exercise prices — through undocumented board decisions or individual negotiations with key employees — without obtaining a fresh valuation at the modification date are systematically under-reporting their compensation expense and will face audit findings when their statutory auditors conduct a thorough Ind AS 102 review.

Stock Appreciation Rights settled in cash — rather than shares — create a mark-to-market liability that is remeasured at every reporting date, creating income statement volatility that is often unexpected by companies that introduce SAR schemes as an alternative to equity-settled ESOPs. For a company whose share value has appreciated significantly, the cumulative SAR liability on the balance sheet can be substantial, and the periodic remeasurement charge can dominate the income statement in periods of strong share price performance. Mumbai-listed companies that have issued large SAR tranches to senior management as part of performance-linked compensation programs must ensure their quarterly reporting reflects the correct remeasurement, calibrated to a contemporaneous equity valuation rather than a year-old report.